Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our choice today is green apple caramel — a new addition to our pantry. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day, and please do stay in touch. …
Moderna disclosed that its Covid-19 vaccine booster targeting the BA.1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months, Reuters notes. Omicron-tailored shots by Pfizer and Moderna are already authorized by regulators in several countries. The U.S. has given the go-ahead for booster vaccines that target the currently circulating BA.4 and BA.5 subvariants of Omicron. Moderna maintained its bivalent booster has durability for at least three months and expects data from human trials of its BA.4/BA.5 targeted vaccine later this year.
Approximately 1.3 million people, or 16.5% of all adults with diabetes in the U.S., rationed their use of insulin in the past year, raising the prospect of harmful and increasingly expensive health consequences, STAT writes, citing a new analysis. Among all insulin users, the most common rationing tactic was to simply delay purchases, with 14.5% of people with diabetes making this decision in response to the cost. Roughly 14% of those with type 1 diabetes took less insulin than needed, compared with 9.5% of those with type 2 diabetes. Rationing occurred most often among those without insurance coverage, at 29%. But nearly 19% of those with private insurance also rationed.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect